Over a month ago |
Hot Stocks
|
Assembly Biosciences… Assembly Biosciences announced promising interim efficacy, safety and pharmacokinetic results from two ongoing clinical studies of its investigational next-generation HBV core inhibitors, a Phase 1b clinical study of ABI-H3733 and a Phase 1a clinical study of ABI-4334. Phase 1b Study for 3733 - Study ABI-H3733-102: The ongoing Phase 1b clinical trial is a randomized, multi-center, double-blind and placebo-controlled study evaluating the safety, PK and antiviral activity of 3733. The dose selected for the first cohort was 50 mg. 50 mg Cohort Efficacy: As of the data cutoff date of December 18, 2022, dosing in the 3733 Phase 1b trial has been completed for all 10 patients in the first cohort of 50 mg. Nine of 10 patients enrolled were HBeAg negative, so efficacy data are provided for these patients. Interim efficacy results from this cohort at the data cutoff date include HBV DNA, HBV RNA and antigen measurements for all patients for the full 28-day dosing period. In the 50 mg cohort, six of eight patients receiving 3733 achieved HBV DNA less than the lower limit of quantification within 21 days, with a mean decline in HBV DNA over the treatment period of approximately 3.1 logs. Data on HBV RNA declines were limited due to low baseline levels in predominantly e-antigen negative patients. 25 mg Cohort Efficacy: The second cohort, evaluating a dose of 25 mg, is fully enrolled. Nine of 10 patients enrolled were HBeAg negative, so efficacy data are provided for these patients. In the five patients that have so far completed 28 days of treatment, the mean reduction in HBV DNA was approximately 1.9 logs. 50 and 25 mg Cohorts: Safety data reported here reflect data received for both cohorts through the data cutoff date. In these initial cohorts, all treatment-emergent adverse events and laboratory abnormalities reported were Grade 1 or Grade 2. Further, no AEs led to treatment discontinuation. The observed PK for the new tablet formulation of 3733 was consistent with predictions from preclinical studies, providing exposure equivalent to the liquid formulation evaluated in the Phase 1a study for 3733. As expected given the 28-day dosing period, limited changes in viral antigens were observed in both the 50 mg and 25 mg cohorts. Phase 1a Study for 4334 - Study ABI-4334-101: The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study evaluating the safety, tolerability and PK of 4334 following single ascending dose and multiple ascending dose administration in healthy subjects. Dosing has completed for all eight subjects in the initial 30 mg single dose cohort. In this cohort, 4334 had a mean half-life of 24 hours, supporting once-a-day dosing. In this initial cohort, treatment-emergent AEs and laboratory abnormalities were mild to moderate and all were considered not related to study treatment. A dose of 100 mg has been selected for the second single-dose cohort. Dosing for the second cohort is complete and initial data from this cohort are anticipated in the first quarter of 2023. ShowHide Related Items >><< ASMB Assembly Biosciences - 11/14/22
- Assembly Biosciences begins dosing in Phase 1a trial of ABI-4334
- 11/04/22
- Assembly Biosciences presents new data as AASLD meeting
- 10/05/22
- Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed
- 08/24/22
- Assembly Biosciences to introduce two new research programs on Aug. 31
ASMB Assembly Biosciences - 11/16/22 Mizuho
- Assembly Biosciences price target lowered to $3 from $14 at Mizuho
- 10/24/22 Truist
- Assembly Biosciences downgraded to Hold from Buy at Truist
- 07/21/22 H.C. Wainwright
- Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
- 04/01/22 Truist
- Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences - 08/09/22
- Assembly Biosciences reports Q2 EPS (51c) vs. (55c) last quarter
|
Recommendations
|
Mizuho analyst Salim Syed… Mizuho analyst Salim Syed lowered the firm's price target on Assembly Biosciences to $3 from $14 and keeps a Buy rating on the shares. The analyst updated his model post the Q3 results. ShowHide Related Items >><< ASMB Assembly Biosciences - 11/14/22
- Assembly Biosciences begins dosing in Phase 1a trial of ABI-4334
- 11/04/22
- Assembly Biosciences presents new data as AASLD meeting
- 10/05/22
- Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed
- 08/24/22
- Assembly Biosciences to introduce two new research programs on Aug. 31
ASMB Assembly Biosciences - 10/24/22 Truist
- Assembly Biosciences downgraded to Hold from Buy at Truist
- 07/21/22 H.C. Wainwright
- Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
- 04/01/22 Truist
- Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences - 08/09/22
- Assembly Biosciences reports Q2 EPS (51c) vs. (55c) last quarter
|
Hot Stocks
|
Assembly Biosciences… Assembly Biosciences announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334. 4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA formation and new virus production versus first-generation core inhibitors. In preclinical research, 4334 has demonstrated sub-nanomolar potency against pgRNA encapsidation and 2-3 nanomolar potency against cccDNA formation. The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics of 4334 following single ascending dose and multiple ascending dose administration in healthy participants. The objectives of the study include the proportion of subjects with adverse events, premature treatment discontinuation due to AEs and abnormal laboratory results. Results of the trial will support dose selection for a future Phase 2 trial. ShowHide Related Items >><< ASMB Assembly Biosciences - 11/04/22
- Assembly Biosciences presents new data as AASLD meeting
- 10/05/22
- Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed
- 08/24/22
- Assembly Biosciences to introduce two new research programs on Aug. 31
- 07/20/22
- Arbutus Biopharma plans to continue dosing in triple combination clinical trial
ASMB Assembly Biosciences - 10/24/22 Truist
- Assembly Biosciences downgraded to Hold from Buy at Truist
- 07/21/22 H.C. Wainwright
- Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
- 04/01/22 Truist
- Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences - 08/09/22
- Assembly Biosciences reports Q2 EPS (51c) vs. (55c) last quarter
|
Conference/Events
|
AASLD 2022: The Liver… AASLD 2022: The Liver Meeting to be held in Washington, DC on November 4-8. ShowHide Related Items >><< - 11/06/22
- Vir presents data on VIR-2218, VIR-3434 potential in chronic HBV infection
- 10/18/22
- Vir Biotechnology announces first patient dosed in Phase 2 trial of VIR-2482
- 10/04/22
- Vir Biotechnology awarded government contract for pandemic preparedness
- 09/22/22
- Vir Biotechnology announces first patient dosed in Phase 2 SOLSTICE trial
- 10/10/22
- Surrozen presents data on two therapeutic candidates at UEG week
- 10/06/22
- Surrozen enter partnership with Boehringer Ingelheim for SZN-413
- 09/26/22
- Surrozen publishes study on SZN-413 in preclinical models of DR
- 06/13/22
- Surrozen initiates dosing in Phase 1 trial of SZN-043
SMMNY Siemens Healthineers - 06/30/22
- Intuitive, Siemens Healthineers boost integration for Ion Endoluminal procedure
- 10/06/22
- Ecolab and Siemens partner to help to reduce greenhouse gas emissions
- 09/27/22
- Siemens obtains UL listing for 120-volt, single pole solid-state circuit breaker
- 07/26/22
- TeamViewer, Siemens partner for product lifecycle management space
- 06/30/22
- Siemens announces impairment related to investment in Siemens Energy AG
- 08/29/22
- Dyne Therapeutics appoints Francesco Bibbiani as SVP, head of development
- 07/19/22
- Ultragenyx trading resumes
- 07/19/22
- Ultragenyx trading halted, volatility trading pause
- 07/18/22
- Ultragenyx provides interim data on GTX-102 study
- 09/22/22
- PerkinElmer Oxford Immunotec gets FDA approval T-Cell Select for TB test
- 08/17/22
- Moderna appoints James Mock as CFO
- 08/17/22
- PerkinElmer CFO Jamey Mock leaving, Max Krakowiak to succeed
- 08/17/22
- Moderna appoints James Mock as CFO
- 11/04/22
- Novo Nordisk purchases B shares worth DKK 3.582B from Novo Holdings
- 10/14/22
- Novo Nordisk announces completion of Forma Therapeutics acquisition
- 10/05/22
- Arch Biopartners adds Farris Smith as strategic advisor
- 10/03/22
- Novo Nordisk reports ONWARDS 5 trial achieved primary endpoint
- 11/07/22
- Lilly announces plans for U.S. rollout of Tempo Personalized Diabetes Management
- 11/04/22
- FDA doesn't see bebtelovimab neutralizing Omicron subvariants BQ.1, BQ.1.1
- 11/04/22
- Eli Lilly reports EMPA-KIDNEY phase 3 clinical trial met primary endpoint
- 11/01/22
- Eli Lilly CEO: Underlying fundamentals of the business are strong
- 10/24/22
- OmniAb business combination approved by Avista Public Acquisition shareholders
- 09/13/22
- Sermonix Pharmaceuticals announces results of Phase 2 study of lasofoxifene
- 08/24/22
- Ligand: Janssen Biotech receives marketing authorization from EC for TECVAYLI
- 11/07/22
- Kamada provides update on progress in Phase 3 trial of inhaled AAT
- 10/19/22
- Kamada awarded $22M extension of Canadian supply tender
- 07/15/22
- Kamada announces resolution to the labor strike at facility in Israel
- 07/06/22
- Kamada secures $11.4M international Varizig procurement agreement
- 11/07/22
- Avalo sells economic rights to previously out-licensed assets for $5M
- 11/01/22
- Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash
- 11/01/22
- J&J: Abiomed acquisition has enterprise value of $16.6B
- 11/01/22
- Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash
- 10/25/22
- Ipsen: Postponement relates to FDA request for new information on trial data
- 10/25/22
- Ipsen: FDA meeting had been scheduled for October 31
- 10/25/22
- Ipsen: FDA postpones planned meeting for investigational palovarotene
- 08/03/22
- Merrimack: Ipsen says primary endpoint not met in Phase 3 Onivyde trial
- 11/07/22
- GSK announces U.S. FDA approves fully liquid presentation of ROTARIX vaccine
- 11/07/22
- GSK reports DREAMM-3 phase III trial for Blenrep did not meet primary endpoint
- 11/03/22
- GSK reports EAGLE-2, EAGLE-3 trials for gepotidacin stopped early for efficacy
- 11/02/22
- Actinium Pharmaceuticals appoints Caroline Yarbrough as Chief Commercial Office
- 10/31/22
- Galecto to present data from GULLIVER-2 clinical trial on GB1211
- 10/19/22
- Galecto enters tinto collaboration agreement for phase 2 trial of GB1211
- 09/29/22
- Galecto reports 'positive' results from ongoing Phase 2a trial of GB2064
- 08/29/22
- Galecto announces publication on Galectin-3 in NSCLC patients
- 11/02/22
- Jounce earns clinical milestone payment under agreement with Gilead
- 11/02/22
- FDA approves Gilead sNDA for Vemlidy to treat pediatric hepatitis B virus
- 10/24/22
- Gilead presents results from the BICSTaR study
- 11/01/22
- Exelixis, Cybrexa establish exclusive collaboration
- 11/01/22
- Exelixis, Sairopa establish development collaboration, option agreement
- 10/26/22
- Exelixis announces initial results from dose-escalation stage of JEWEL-101
- 10/04/22
- Exelixis expands pact with Bristol-Myers for STELLAR-002 trial with combos
- 11/02/22
- Cathie Wood's ARK Investment bought 106.8K shares of Exact Sciences today
- 11/01/22
- Cathie Wood's ARK Investment bought 104K shares of Exact Sciences today
- 09/10/22
- Exact Sciences announces data from MCED biomaker validation study
- 09/06/22
- Cathie Wood's ARK Investment bought 188K shares of Exact Sciences today
CALT Calliditas Therapeutics - 10/19/22
- Calliditas Therapeutics announces publication of results from NefIgArd Part A
- 09/20/22
- Calliditas' partner STADA launches Nefecon in the EU
- 07/15/22
- European Commission approves Kinpeygo for adults with primary IgAN
- 07/07/22
- Calliditas Therapeutics to highlight IgA nephropathy at various events
- 11/07/22
- Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports
- 11/03/22
- Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital
- 10/31/22
- Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints
- 10/27/22
- Obsidian Therapeutics announces extension of agreement with Bristol-Myers
- 11/07/22
- BioMarin provides update on BLA for valoctocogene roxaparvovec AAV gene therapy
- 10/12/22
- FDA accepts BioMarin's BLA for valoctocogene roxaparvovec AAV gene therapy
- 10/06/22
- BioMarin redesigns organization, will lay off about 4% of its workforce
- 09/29/22
- BioMarin submits BLA to FDA for valoctocogene roxaparvovec
- 10/12/22
- Regeneron announces U.S. FDA accepted for priority review the sBLA for EYLEA
- 09/27/22
- GXO Logistics expands warehouse services for Bayer
- 09/08/22
- Regeneron announces primary endpoints met in PHOTON, PULSAR trials
- 09/02/22
- Bayer pays $40M to resolve False Claims Act allegations
- 09/29/22
- Axcella Health's AXA1125 shows efficacy in Phase 2b NASH trial
- 08/02/22
- Axcella Health reports results from Phase 2a investigation for AXA1125
- 05/26/22
- Axcella done enrolling of trial for long COVID and prioritize portfolio
ASMB Assembly Biosciences - 11/04/22
- Assembly Biosciences presents new data as AASLD meeting
- 10/05/22
- Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed
- 08/24/22
- Assembly Biosciences to introduce two new research programs on Aug. 31
- 07/20/22
- Arbutus Biopharma plans to continue dosing in triple combination clinical trial
- 10/12/22
- Alexion, AstraZeneca Rare Disease to present new Ultomiris data
- 10/03/22
- Alexion, AstraZeneca Rare Disease to acquire LogicBio for $2.07 per share
- 09/28/22
- Altimmune announces first dosing of all subjects in Phase 2 MOMENTUM trial
- 09/14/22
- Altimmune down 58% in pre-market after results of Phase 1b study of pemvidutide
- 09/14/22
- Altimmune announces results from Phase 1b study of pemvidutide
- 09/14/22
- Altimmune announces results from Phase 1b study of pemvidutide
- 10/27/22
- Alnylam won't initiate Phase 3 study of vutrisiran as planned
- 10/06/22
- Alnylam announces FDA approval of Oxlumo in primary hyperoxaluria
- 10/04/22
- Biohaven launches as a new publicly traded company
- 09/30/22
- Alnylam presents additional results from APOLLO-B Phase 3 study
- 11/01/22
- Alimera announces reimbursement of uveitis indication granted to ILUVIEN
- 10/06/22
- Alimera Sciences says ILUVIEN patients show reduced need for multiple treatments
- 09/23/22
- Alimera announces agreement with JCHR for health research
- 09/20/22
- Alimera reimbursement of uveitis indication granted for ILUVIEN in Ireland
- 11/04/22
- Aligos Therapeutics presents data for its Capsid Assembly Modulator
- 11/04/22
- Aligos Therapeutics presents data for its NASH program, Hepatitis B portfolio
- 10/21/22
- Aligos Therapeutics to present data for CHB, NASH portfolio at The Liver Meeting
- 10/18/22
- Aligos Therapeutics to present data on pan-coronavirus protease inhibitors
- 11/07/22
- Albireo Pharma presented data on Bylvay at the AASLD The Liver Meeting
- 11/02/22
- Albireo Pharma completes Phase 3 BOLD study enrollment
- 11/01/22
- Albireo Pharma to present late breaking Bylvay data at AASLD 2022
- 10/13/22
- Albireo Pharma presents data from Phase 3 PEDFIC 1, PEDFIC 2 trials
- 04/26/22 Bernstein
- Wuxi Biologics initiated with an Outperform at Bernstein
- 09/14/22 SVB Securities
- SVB Securities bullish on Vir Biotechnology, initiates with an Outperform
- 09/14/22 SVB Securities
- Vir Biotechnology initiated with an Outperform at SVB Securities
- 09/09/22 Morgan Stanley
- Vir Biotechnology initiated with an Underweight at Morgan Stanley
- 05/12/22 H.C. Wainwright
- Vir Biotechnology price target lowered to $125 from $250 at H.C. Wainwright
- 10/17/22 JPMorgan
- Surrozen initiated with a Neutral at JPMorgan
- 05/27/22 BofA
- Surrozen downgraded to Neutral from Buy at BofA
- 10/25/22 H.C. Wainwright
- Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
- 10/25/22 Barclays
- Ligand price target lowered to $150 from $157 at Barclays
- 09/02/22 Roth MKM
- Ligand price target lowered to $175 from $185 at Roth Capital
- 07/05/22 Barclays
- Ligand price target lowered to $157 from $165 at Barclays
- 11/02/22 Wells Fargo
- Eli Lilly price target raised to $365 from $305 at Wells Fargo
- 11/02/22 Barclays
- Eli Lilly price target raised to $395 from $355 at Barclays
- 11/01/22 Piper Sandler
- AbCellera price target lowered to $21 from $22 at Piper Sandler
- 10/18/22 Piper Sandler
- Akouos downgraded to Neutral from Overweight at Piper Sandler
- 11/02/22 Cowen
- Exelixis price target lowered to $21 from $26 at Cowen
- 10/31/22 EF Hutton
- Exelixis initiated with a Buy at EF Hutton
- 10/18/22 JMP Securities
- Exelixis initiated with an Outperform at JMP Securities
- 10/12/22 Guggenheim
- Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim
- 11/07/22 Raymond James
- Exact Sciences price target lowered to $60 from $70 at Raymond James
- 11/07/22 BTIG
- Exact Sciences price target lowered to $65 from $70 at BTIG
- 11/04/22 Baird
- Exact Sciences price target lowered to $60 from $75 at Baird
- 11/04/22 Citi
- Exact Sciences price target lowered to $35 from $50 at Citi
- 10/26/22 Morgan Stanley
- Bayer price target raised to EUR 81 from EUR 80 at Morgan Stanley
- 10/25/22 Capital One
- Arvinas initiated with an Overweight at Capital One
- 10/12/22 Redburn
- Bayer upgraded to Buy from Neutral at Redburn
- 09/07/22 Morgan Stanley
- Bayer price target lowered to EUR 80 from EUR 87 at Morgan Stanley
- 10/31/22 Oppenheimer
- BioMarin upgraded to Outperform from Perform at Oppenheimer
- 10/26/22 Piper Sandler
- Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
- 10/24/22 JPMorgan
- BioMarin price target lowered to $112 from $140 at JPMorgan
- 10/13/22 RBC Capital
- BioMarin price target raised to $95 from $90 at RBC Capital
- 11/02/22 Evercore ISI
- Evercore starts Legend Biotech with an Outperform on Carvykti potential
- 10/31/22 Guggenheim
- 2seventy Bio initiated with a Buy at Guggenheim
- 10/12/22 Barclays
- Bristol-Myers price target lowered to $66 from $69 at Barclays
- 10/10/22 Guggenheim
- Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
CALT Calliditas Therapeutics - 06/16/22 Kepler Cheuvreux
- Calliditas Therapeutics initiated with a Buy at Kepler Cheuvreux
- 06/02/22 Pareto
- Calliditas Therapeutics initiated with a Buy at Pareto
- 03/15/22 Citi
- Calliditas Therapeutics price target lowered to $76 from $84 at Citi
- 12/20/21 H.C. Wainwright
- Calliditas price target raised to $62 from $52 at H.C. Wainwright
- 10/24/22 Piper Sandler
- Mirum's LIVMARLI PFIC data shows superiority to Albireo's Bylvay, says Piper
- 10/12/22 H.C. Wainwright
- Albireo Pharma price target raised to $68 from $54 at H.C. Wainwright
- 10/12/22 Baird
- Albireo Pharma price target raised to $55 from $43
- 10/11/22 Piper Sandler
- Piper says Bylvay safety, efficacy look similar to Mirum's Livmarli
- 08/08/22 Cantor Fitzgerald
- Aligos Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- 05/05/22 SVB Securities
- Aligos Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
- 03/22/22 Piper Sandler
- Aligos Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- 01/07/22 JPMorgan
- Aligos Therapeutics downgraded to Neutral from Overweight at JPMorgan
- 07/28/22 H.C. Wainwright
- Alimera Sciences price target raised to $9 from $8 at H.C. Wainwright
- 05/10/22 H.C. Wainwright
- Alimera Sciences price target lowered to $8 from $10 at H.C. Wainwright
- 02/25/22 Alliance Global Partners
- Alimera price target lowered to $11 from $14.50 at Alliance Global Partners
- 02/25/22 H.C. Wainwright
- Alimera Sciences price target lowered to $10 from $12 at H.C. Wainwright
- 11/02/22 H.C. Wainwright
- Alnylam price target lowered to $415 from $430 at H.C. Wainwright
- 10/24/22 JPMorgan
- Alnylam price target lowered to $200 from $204 at JPMorgan
- 10/07/22 BMO Capital
- Alnylam's Oxlumo label expansion modest positive for franchise, says BMO Capital
- 10/03/22 Jefferies
- Alnylam price target raised to $232 from $218 at Jefferies
- 09/16/22 Guggenheim
- Altimmune price target lowered to $26 from $31 at Guggenheim
- 09/16/22 H.C. Wainwright
- Altimmune selloff post Phase 1 data overdone, says H.C. Wainwright
- 09/14/22 Evercore ISI
- Altimmune a 'reasonable buy on weakness,' says Evercore ISI
- 09/14/22 Piper Sandler
- Piper says conviction in pemvidutide stronger after call with Altimmune team
ASMB Assembly Biosciences - 10/24/22 Truist
- Assembly Biosciences downgraded to Hold from Buy at Truist
- 07/21/22 H.C. Wainwright
- Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
- 04/01/22 Truist
- Assembly Biosciences price target lowered to $12 from $15 at Truist
- 11/02/22 Chardan
- Axcella Health price target lowered to $5 from $7 at Chardan
- 11/02/22 H.C. Wainwright
- Axcella Health price target lowered to $8 from $10 at H.C. Wainwright
- 09/29/22 Roth MKM
- Roth reiterates $19 target on Axcella after 'encouraging' data
- 08/03/22 H.C. Wainwright
- Axcella Health price target lowered to $8 from $14 at H.C. Wainwright
- 11/02/22 Morgan Stanley
- Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
- 11/02/22 Deutsche Bank
- Abiomed downgraded to Hold from Buy at Deutsche Bank
- 11/01/22 Piper Sandler
- Abiomed downgraded to Neutral from Overweight at Piper Sandler
- 11/01/22 Cowen
- Cowen starts Legend Biotech with an Outperform on Carvykti potential
- 11/03/22 UBS
- Ipsen price target raised to EUR 107 from EUR 102 at UBS
- 11/01/22 Societe Generale
- Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
- 10/31/22 Societe Generale
- Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
- 10/28/22 RBC Capital
- Ipsen price target raised to EUR 108 from EUR 107 at RBC Capital
- 09/23/22 H.C. Wainwright
- Inventiva price target lowered to $36 from $42 at H.C. Wainwright
- 03/09/22 Roth MKM
- Roth Capital sees Inventiva as 'attractive acquisition target'
- 11/22/21 H.C. Wainwright
- Inventiva price target raised to $42 from $40 at H.C. Wainwright
- 10/27/22 Oppenheimer
- Simulations Plus price target lowered to $65 from $75 at Oppenheimer
- 07/07/22 Craig-Hallum
- Simulations Plus price target raised to $60 from $55 at Craig-Hallum
- 01/03/22 Sidoti
- Simulations Plus reinstated with a Neutral at Sidoti
SMMNY Siemens Healthineers - 10/18/22 Morgan Stanley
- Siemens Healthineers initiated with an Overweight at Morgan Stanley
- 10/04/22 Barclays
- Siemens Healthineers price target lowered to EUR 62 from EUR 64 at Barclays
- 08/25/22 UBS
- Siemens Healthineers upgraded to Buy from Neutral at UBS
- 08/05/22 Societe Generale
- Siemens Healthineers price target lowered to EUR 62.90 from EUR 64.20 at Societe Generale
- 10/14/22 Societe Generale
- Siemens downgraded on 'too complacent' consensus at Societe Generale
- 10/14/22 Societe Generale
- Siemens downgraded to Hold from Buy at Societe Generale
- 10/04/22 Deutsche Bank
- Siemens price target lowered to EUR 145 from EUR 160 at Deutsche Bank
- 10/03/22 Barclays
- Siemens price target lowered to EUR 90 from EUR 95 at Barclays
- 11/03/22 Baird
- Ultragenyx upgraded to Outperform from Neutral at Baird
- 11/03/22 Cowen
- Ultragenyx price target lowered to $65 from $86 at Cowen
- 11/03/22 Credit Suisse
- Ultragenyx price target lowered to $96 from $105 at Credit Suisse
- 10/13/22 Guggenheim
- Ultragenyx upgraded to Buy from Neutral at Guggenheim
- 10/06/22 Barclays
- PerkinElmer price target lowered to $120 from $140 at Barclays
- 09/12/22 Barclays
- PerkinElmer price target lowered to $140 from $149 at Barclays
- 08/24/22 Credit Suisse
- PerkinElmer initiated with a Neutral at Credit Suisse
- 08/18/22 Stifel
- PerkinElmer downgraded to Hold on CFO exit at Stifel
- 11/03/22 Credit Suisse
- Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
- 10/14/22 Barclays
- Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
- 09/28/22 Oddo BHF
- Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
- 09/14/22 Piper Sandler
- Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
- 10/14/22 Barclays
- GSK price target lowered to 1,450 GBp from 1,800 GBp at Barclays
- 10/12/22 Morgan Stanley
- GSK price target raised to 1,650 GBp from 1,550 GBp at Morgan Stanley
- 09/29/22 Oddo BHF
- GSK upgraded to Outperform from Neutral at Oddo BHF
- 09/22/22 Evercore ISI
- Evercore upgrades Spero, quadruples target on GSK partnership
- 11/01/22 Guggenheim
- AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
- 10/31/22 Maxim
- Gilead price target raised to $92 from $84 at Maxim
- 10/31/22 Barclays
- Gilead upgraded to Equal Weight from Underweight at Barclays
- 10/28/22 BMO Capital
- Gilead price target raised to $72 from $63 at BMO Capital
- 11/03/22
- Vir Biotechnology reports Q3 EPS $1.30, consensus (21c)
- 08/09/22
- Vir Biotechnology reports Q2 EPS (58c), consensus 10c
- 08/11/22
- Surrozen reports Q2 EPS (40c) vs (69c) last year
- 05/11/22
- Surrozen reports Q1 EPS (23c), consensus (50c)
- 10/26/22
- Simulations Plus sees FY23 EPS 63c-67c, consensus 71c
- 10/26/22
- Simulations Plus reports Q4 EPS 5c, consensus 7c
- 07/06/22
- Simulations Plus backs FY22 revenue view $52M-$53M, consensus $52.9M
- 07/06/22
- Simulations Plus reports Q3 EPS 20c, consensus 17c
- 11/02/22
- Ultragenyx reports Q3 EPS ($3.50), consensus ($1.81)
- 07/28/22
- Ultragenyx reports Q2 EPS ($2.26), consensus ($1.75)
- 08/01/22
- PerkinElmer raises FY22 adjusted EPS view to $7.80-$7.90 from $6.80-$7.00
- 08/01/22
- PerkinElmer sees Q3 adjusted EPS $1.40-1.45, consensus $1.34
- 08/01/22
- PerkinElmer reports Q2 adjusted EPS $2.32, consensus $2.02
- 11/02/22
- Novo Nordisk reports 9-month EPS DKK18.42 vs. DKK15.98 last year
- 08/03/22
- Novo Nordisk raises 2022 sales growth outlook to 12%-16%
- 08/03/22
- Novo Nordisk reports Q2 EBIT DKK 18.39B, consensus DKK 18.13B
- 11/01/22
- Eli Lilly cuts FY22 EPS view to $7.70-$7.85 from $7.90-$8.05, consensus $7.99
- 11/01/22
- Eli Lilly reports Q3 EPS $1.98, consensus $1.96
- 10/31/22
- Notable companies reporting before tomorrow's open
- 11/07/22
- Ligand sees FY22 adjusted EPS $2.05-$2.20, consensus $2.79
- 11/07/22
- Ligand reports Q3 adjusted EPS 41c, consensus 43c
- 08/08/22
- Ligand boosts FY22 revenue view for combined business
- 08/08/22
- Ligand reports Q2 adjusted EPS $1.03, consensus 43c
- 08/17/22
- Kamada reaffirms FY22 revenue view $125M-$135M
- 08/17/22
- Kamada reports Q2 EPS (9c) vs 2c last year
- 05/17/22
- Kamada reaffirms FY22 revenue view $125M-$135M
- 05/17/22
- Kamada reports Q1 EPS (4c) vs 6c last year
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
- 11/02/22
- GSK reports Q3 adjusted EPS 46.9p, up 25% AER, 11% CER
- 07/27/22
- GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
- 07/29/22
- Galecto reports Q2 EPS (67c) vs. (49c) last year
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- 08/02/22
- Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70
- 11/01/22
- Exelixis sees FY22 revenue $1.575B-$1.6B, consensus $1.6B
- 11/01/22
- Exelixis reports Q3 adjusted EPS 31c, consensus 19c
- 08/09/22
- Exelixis reports Q2 EPS 28c, consensus 19c
- 05/10/22
- Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B
- 11/03/22
- Exact Sciences raises FY22 revenue view to $2.025B-$2.042B, consensus $2.01B
- 11/03/22
- Exact Sciences reports Q3 EPS (84c), consensus ($1.08)
- 08/02/22
- Exact Sciences lowers FY22 revenue view to $1.980B-$2.022B from $1.985B-$2.032B
- 08/02/22
- Exact Sciences reports Q2 EPS (94c), consensus ($1.07)
- 10/25/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51
- 10/25/22
- Bristol-Myers reports Q3 EPS $1.99, consensus $1.83
- 10/26/22
- BioMarin backs FY22 revenue view $2.06B-$2.16B, consensus $2.12B
- 10/26/22
- BioMarin reports Q3 GAAP EPS (4c), consensus (1c)
- 10/26/22
- Notable companies reporting after market close
- 08/03/22
- BioMarin raises FY22 revenue view to $2.06B-$2.16B from $2.05B-$2.15B
- 08/04/22
- Bayer raises FY core EPS view to EUR7.30 vs. EUR7.00 previously
- 08/04/22
- Bayer reports Q2 core EPS EUR1.93 vs. EUR1.61 last year
- 05/10/22
- Bayer reports Q1 core EPS EUR 3.53 vs. EUR 2.59 last year
- 11/01/22
- Axcella Health reports Q3 EPS (34c), consensus (38c)
- 08/12/22
- Axcella Health reports Q2 EPS (40c), consensus (38c)
ASMB Assembly Biosciences - 08/09/22
- Assembly Biosciences reports Q2 EPS (51c) vs. (55c) last quarter
- 05/12/22
- Assembly Biosciences reports Q1 EPS (48c), consensus (47c)
- 08/11/22
- Altimmune reports Q2 EPS (42c) vs (60c) last year
- 05/12/22
- Altimmune reports Q1 EPS (44c), consensus (58c)
- 10/27/22
- Alnylam reports Q3 EPS ($1.58), consensus ($1.77)
- 07/28/22
- Alnylam reports Q2 EPS ($2.03), consensus ($1.63)
- 07/27/22
- Alimera Sciences reports Q2 EPS (45c), consensus (55c)
- 05/09/22
- Alimera Sciences reports Q1 EPS (85c) vs (63c) last year
- 11/02/22
- Aligos Therapeutics reports Q3 EPS (44c), consensus (58c)
- 08/15/22
- Albireo Pharma reports Q2 EPS ($2.04), consensus ($1.65)
- 05/16/22
- Albireo Pharma reports Q1 EPS ($2.19), consensus ($1.85)
- 09/16/22
- WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports
- 06/27/22
- VW close to deal to sell Electrify America interest to Siemens, WSJ reports
- 07/09/22
- Eli Lilly's growth set to soar under CEO Ricks, Barron's says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 10/11/22
- New quality issues found at Eli Lilly drug plant, Reuters reports
- 08/13/22
- Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says
- 08/03/22
- Eli Lilly to begin commercial sales of COVID-19 antibody, WSJ reports
- 11/07/22
- Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says
- 10/20/22
- CDC panel says COVID shots to be added to regular vaccinations, WSJ says
- 10/18/22
- Johnson & Johnson likely to make 'modest' cuts to workforce, WSJ reports
- 08/20/22
- Buy Haleon on steady growth, planned dividend, Barron's says
- 08/17/22
- Generic drugmakers paid to settle first Zantac case before trial, Bloomberg says
- 06/24/22
- Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says
- 06/14/22
- FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says
- 05/28/22
- Buy Bristol-Myers, rally just getting started, Barron's says
- 09/13/22
- Bayer quietly starts search for new CEO, Bloomberg reports
- 06/27/22
- Supreme Court lets $87M award against Bayer for Roundup stand, Bloomberg reports
- 06/21/22
- Supreme Court rejects Bayer bid to end Roundup suits, Bloomberg reports
- 05/11/22
- Biden administration asks Supreme Court to reject Roundup appeal, Reuters says
- 08/09/22
- Fly Intel: After-Hours Movers
- 11/03/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/19/22
- What You Missed On Wall Street On Tuesday
- 07/19/22
- What You Missed On Wall Street This Morning
- 08/01/22
- What You Missed On Wall Street On Monday
- 08/01/22
- What You Missed On Wall Street This Morning
- 08/01/22
- Fly Intel: Pre-market Movers
- 07/05/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/03/22
- Biotech Alert: Searches spiking for these stocks today
- 09/01/22
- What You Missed On Wall Street On Thursday
- 09/01/22
- What You Missed On Wall Street This Morning
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 11/01/22
- What You Missed On Wall Street This Morning
- 11/01/22
- Fly Intel: Pre-market Movers
- 10/18/22
- What You Missed On Wall Street On Tuesday
- 11/04/22
- Biotech Alert: Searches spiking for these stocks today
- 05/17/22
- What You Missed On Wall Street This Morning
- 11/02/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/26/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/03/22
- Biotech Alert: Searches spiking for these stocks today
- 09/23/22
- What You Missed On Wall Street On Friday
- 09/23/22
- What You Missed On Wall Street This Morning
- 09/16/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street This Morning
- 10/04/22
- Fly Intel: Pre-market Movers
- 11/04/22
- What You Missed On Wall Street On Friday
- 11/04/22
- What You Missed On Wall Street This Morning
- 10/19/22
- What You Missed On Wall Street On Wednesday
- 10/19/22
- What You Missed On Wall Street This Morning
- 10/26/22
- What You Missed On Wall Street On Wednesday
- 10/26/22
- What You Missed On Wall Street This Morning
- 10/26/22
- Fly Intel: Pre-market Movers
- 10/20/22
- Meet PDS Biotechnology: Fly exclusive interview with CEO Frank Bedu-Addo
- 11/05/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 10/31/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/26/22
- Fly Intel: After-Hours Movers
- 10/12/22
- Fly Intel: After-Hours Movers
- 09/13/22
- What You Missed On Wall Street On Tuesday
- 09/13/22
- What You Missed On Wall Street This Morning
- 06/27/22
- What You Missed On Wall Street On Monday
- 06/27/22
- What You Missed On Wall Street This Morning
- 09/14/22
- What You Missed On Wall Street On Wednesday
- 09/14/22
- What You Missed On Wall Street This Morning
- 09/14/22
- Fly Intel: Pre-market Movers
- 09/09/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/03/22
- What You Missed On Wall Street On Wednesday
- 08/03/22
- What You Missed On Wall Street This Morning
- 08/03/22
- Fly Intel: Pre-market Movers
- 10/13/22
- Biotech Alert: Searches spiking for these stocks today
- 08/16/22
- What You Missed On Wall Street On Tuesday
- 08/16/22
- What You Missed On Wall Street This Morning
- 08/16/22
- Fly Intel: Pre-market Movers
- 08/01/22
- Early notable gainers among liquid option names on August 1st
- 07/21/22
- Early notable gainers among liquid option names on July 21st
- 11/01/22
- Unusually active option classes on open November 1st
- 10/03/22
- Eli Lilly And Co put volume heavy and directionally bearish
- 09/28/22
- Early notable gainers among liquid option names on September 28th
- 09/28/22
- Unusually active option classes on open September 28th
- 10/18/22
- Unusually active option classes on open October 18th
- 09/20/22
- Johnson & Johnson put volume heavy and directionally bearish
- 07/19/22
- Unusually active option classes on open July 19th
- 06/28/22
- Johnson & Johnson put volume heavy and directionally bearish
- 11/07/22
- GSK Pharma put volume heavy and directionally bearish
- 11/02/22
- Unusually active option classes on open November 2nd
- 09/23/22
- GSK Pharma call volume above normal and directionally bullish
- 08/15/22
- GSK plc (ADR) call volume above normal and directionally bullish
- 10/28/22
- Early notable gainers among liquid option names on October 28th
- 10/27/22
- Gilead options imply 2.6% move in share price post-earnings
- 09/30/22
- Unusually active option classes on open September 30th
- 08/02/22
- EXACT Sciences options imply 7.0% move in share price post-earnings
- 09/29/22
- Early notable gainers among liquid option names on September 29th
- 09/12/22
- Early notable gainers among liquid option names on September 12th
- 09/12/22
- Unusually active option classes on open September 12th
- 09/08/22
- Notable open interest changes for September 8th
- 09/13/22
- Altimmune call volume above normal and directionally bullish
- 09/12/22
- Altimmune put volume heavy and directionally bearish
|
Conference/Events
|
AASLD 2022: The Liver… AASLD 2022: The Liver Meeting to be held in Washington, DC on November 4-8. ShowHide Related Items >><< - 11/06/22
- Vir presents data on VIR-2218, VIR-3434 potential in chronic HBV infection
- 10/18/22
- Vir Biotechnology announces first patient dosed in Phase 2 trial of VIR-2482
- 10/04/22
- Vir Biotechnology awarded government contract for pandemic preparedness
- 09/22/22
- Vir Biotechnology announces first patient dosed in Phase 2 SOLSTICE trial
- 10/10/22
- Surrozen presents data on two therapeutic candidates at UEG week
- 10/06/22
- Surrozen enter partnership with Boehringer Ingelheim for SZN-413
- 09/26/22
- Surrozen publishes study on SZN-413 in preclinical models of DR
- 06/13/22
- Surrozen initiates dosing in Phase 1 trial of SZN-043
SMMNY Siemens Healthineers - 06/30/22
- Intuitive, Siemens Healthineers boost integration for Ion Endoluminal procedure
- 10/06/22
- Ecolab and Siemens partner to help to reduce greenhouse gas emissions
- 09/27/22
- Siemens obtains UL listing for 120-volt, single pole solid-state circuit breaker
- 07/26/22
- TeamViewer, Siemens partner for product lifecycle management space
- 06/30/22
- Siemens announces impairment related to investment in Siemens Energy AG
- 08/29/22
- Dyne Therapeutics appoints Francesco Bibbiani as SVP, head of development
- 07/19/22
- Ultragenyx trading resumes
- 07/19/22
- Ultragenyx trading halted, volatility trading pause
- 07/18/22
- Ultragenyx provides interim data on GTX-102 study
- 09/22/22
- PerkinElmer Oxford Immunotec gets FDA approval T-Cell Select for TB test
- 08/17/22
- Moderna appoints James Mock as CFO
- 08/17/22
- PerkinElmer CFO Jamey Mock leaving, Max Krakowiak to succeed
- 08/17/22
- Moderna appoints James Mock as CFO
- 11/04/22
- Novo Nordisk purchases B shares worth DKK 3.582B from Novo Holdings
- 10/14/22
- Novo Nordisk announces completion of Forma Therapeutics acquisition
- 10/05/22
- Arch Biopartners adds Farris Smith as strategic advisor
- 10/03/22
- Novo Nordisk reports ONWARDS 5 trial achieved primary endpoint
- 11/07/22
- Lilly announces plans for U.S. rollout of Tempo Personalized Diabetes Management
- 11/04/22
- FDA doesn't see bebtelovimab neutralizing Omicron subvariants BQ.1, BQ.1.1
- 11/04/22
- Eli Lilly reports EMPA-KIDNEY phase 3 clinical trial met primary endpoint
- 11/01/22
- Eli Lilly CEO: Underlying fundamentals of the business are strong
- 10/24/22
- OmniAb business combination approved by Avista Public Acquisition shareholders
- 09/13/22
- Sermonix Pharmaceuticals announces results of Phase 2 study of lasofoxifene
- 08/24/22
- Ligand: Janssen Biotech receives marketing authorization from EC for TECVAYLI
- 11/07/22
- Kamada provides update on progress in Phase 3 trial of inhaled AAT
- 10/19/22
- Kamada awarded $22M extension of Canadian supply tender
- 07/15/22
- Kamada announces resolution to the labor strike at facility in Israel
- 07/06/22
- Kamada secures $11.4M international Varizig procurement agreement
- 11/07/22
- Avalo sells economic rights to previously out-licensed assets for $5M
- 11/01/22
- Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash
- 11/01/22
- J&J: Abiomed acquisition has enterprise value of $16.6B
- 11/01/22
- Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash
- 10/25/22
- Ipsen: Postponement relates to FDA request for new information on trial data
- 10/25/22
- Ipsen: FDA meeting had been scheduled for October 31
- 10/25/22
- Ipsen: FDA postpones planned meeting for investigational palovarotene
- 08/03/22
- Merrimack: Ipsen says primary endpoint not met in Phase 3 Onivyde trial
- 11/07/22
- GSK announces U.S. FDA approves fully liquid presentation of ROTARIX vaccine
- 11/07/22
- GSK reports DREAMM-3 phase III trial for Blenrep did not meet primary endpoint
- 11/03/22
- GSK reports EAGLE-2, EAGLE-3 trials for gepotidacin stopped early for efficacy
- 11/02/22
- Actinium Pharmaceuticals appoints Caroline Yarbrough as Chief Commercial Office
- 10/31/22
- Galecto to present data from GULLIVER-2 clinical trial on GB1211
- 10/19/22
- Galecto enters tinto collaboration agreement for phase 2 trial of GB1211
- 09/29/22
- Galecto reports 'positive' results from ongoing Phase 2a trial of GB2064
- 08/29/22
- Galecto announces publication on Galectin-3 in NSCLC patients
- 11/02/22
- Jounce earns clinical milestone payment under agreement with Gilead
- 11/02/22
- FDA approves Gilead sNDA for Vemlidy to treat pediatric hepatitis B virus
- 10/24/22
- Gilead presents results from the BICSTaR study
- 11/01/22
- Exelixis, Cybrexa establish exclusive collaboration
- 11/01/22
- Exelixis, Sairopa establish development collaboration, option agreement
- 10/26/22
- Exelixis announces initial results from dose-escalation stage of JEWEL-101
- 10/04/22
- Exelixis expands pact with Bristol-Myers for STELLAR-002 trial with combos
- 11/02/22
- Cathie Wood's ARK Investment bought 106.8K shares of Exact Sciences today
- 11/01/22
- Cathie Wood's ARK Investment bought 104K shares of Exact Sciences today
- 09/10/22
- Exact Sciences announces data from MCED biomaker validation study
- 09/06/22
- Cathie Wood's ARK Investment bought 188K shares of Exact Sciences today
CALT Calliditas Therapeutics - 10/19/22
- Calliditas Therapeutics announces publication of results from NefIgArd Part A
- 09/20/22
- Calliditas' partner STADA launches Nefecon in the EU
- 07/15/22
- European Commission approves Kinpeygo for adults with primary IgAN
- 07/07/22
- Calliditas Therapeutics to highlight IgA nephropathy at various events
- 11/07/22
- Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports
- 11/03/22
- Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital
- 10/31/22
- Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints
- 10/27/22
- Obsidian Therapeutics announces extension of agreement with Bristol-Myers
- 11/07/22
- BioMarin provides update on BLA for valoctocogene roxaparvovec AAV gene therapy
- 10/12/22
- FDA accepts BioMarin's BLA for valoctocogene roxaparvovec AAV gene therapy
- 10/06/22
- BioMarin redesigns organization, will lay off about 4% of its workforce
- 09/29/22
- BioMarin submits BLA to FDA for valoctocogene roxaparvovec
- 10/12/22
- Regeneron announces U.S. FDA accepted for priority review the sBLA for EYLEA
- 09/27/22
- GXO Logistics expands warehouse services for Bayer
- 09/08/22
- Regeneron announces primary endpoints met in PHOTON, PULSAR trials
- 09/02/22
- Bayer pays $40M to resolve False Claims Act allegations
- 09/29/22
- Axcella Health's AXA1125 shows efficacy in Phase 2b NASH trial
- 08/02/22
- Axcella Health reports results from Phase 2a investigation for AXA1125
- 05/26/22
- Axcella done enrolling of trial for long COVID and prioritize portfolio
ASMB Assembly Biosciences - 11/04/22
- Assembly Biosciences presents new data as AASLD meeting
- 10/05/22
- Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed
- 08/24/22
- Assembly Biosciences to introduce two new research programs on Aug. 31
- 07/20/22
- Arbutus Biopharma plans to continue dosing in triple combination clinical trial
- 10/12/22
- Alexion, AstraZeneca Rare Disease to present new Ultomiris data
- 10/03/22
- Alexion, AstraZeneca Rare Disease to acquire LogicBio for $2.07 per share
- 09/28/22
- Altimmune announces first dosing of all subjects in Phase 2 MOMENTUM trial
- 09/14/22
- Altimmune down 58% in pre-market after results of Phase 1b study of pemvidutide
- 09/14/22
- Altimmune announces results from Phase 1b study of pemvidutide
- 09/14/22
- Altimmune announces results from Phase 1b study of pemvidutide
- 10/27/22
- Alnylam won't initiate Phase 3 study of vutrisiran as planned
- 10/06/22
- Alnylam announces FDA approval of Oxlumo in primary hyperoxaluria
- 10/04/22
- Biohaven launches as a new publicly traded company
- 09/30/22
- Alnylam presents additional results from APOLLO-B Phase 3 study
- 11/01/22
- Alimera announces reimbursement of uveitis indication granted to ILUVIEN
- 10/06/22
- Alimera Sciences says ILUVIEN patients show reduced need for multiple treatments
- 09/23/22
- Alimera announces agreement with JCHR for health research
- 09/20/22
- Alimera reimbursement of uveitis indication granted for ILUVIEN in Ireland
- 11/04/22
- Aligos Therapeutics presents data for its Capsid Assembly Modulator
- 11/04/22
- Aligos Therapeutics presents data for its NASH program, Hepatitis B portfolio
- 10/21/22
- Aligos Therapeutics to present data for CHB, NASH portfolio at The Liver Meeting
- 10/18/22
- Aligos Therapeutics to present data on pan-coronavirus protease inhibitors
- 11/07/22
- Albireo Pharma presented data on Bylvay at the AASLD The Liver Meeting
- 11/02/22
- Albireo Pharma completes Phase 3 BOLD study enrollment
- 11/01/22
- Albireo Pharma to present late breaking Bylvay data at AASLD 2022
- 10/13/22
- Albireo Pharma presents data from Phase 3 PEDFIC 1, PEDFIC 2 trials
- 04/26/22 Bernstein
- Wuxi Biologics initiated with an Outperform at Bernstein
- 09/14/22 SVB Securities
- SVB Securities bullish on Vir Biotechnology, initiates with an Outperform
- 09/14/22 SVB Securities
- Vir Biotechnology initiated with an Outperform at SVB Securities
- 09/09/22 Morgan Stanley
- Vir Biotechnology initiated with an Underweight at Morgan Stanley
- 05/12/22 H.C. Wainwright
- Vir Biotechnology price target lowered to $125 from $250 at H.C. Wainwright
- 10/17/22 JPMorgan
- Surrozen initiated with a Neutral at JPMorgan
- 05/27/22 BofA
- Surrozen downgraded to Neutral from Buy at BofA
- 10/25/22 H.C. Wainwright
- Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
- 10/25/22 Barclays
- Ligand price target lowered to $150 from $157 at Barclays
- 09/02/22 Roth MKM
- Ligand price target lowered to $175 from $185 at Roth Capital
- 07/05/22 Barclays
- Ligand price target lowered to $157 from $165 at Barclays
- 11/02/22 Wells Fargo
- Eli Lilly price target raised to $365 from $305 at Wells Fargo
- 11/02/22 Barclays
- Eli Lilly price target raised to $395 from $355 at Barclays
- 11/01/22 Piper Sandler
- AbCellera price target lowered to $21 from $22 at Piper Sandler
- 10/18/22 Piper Sandler
- Akouos downgraded to Neutral from Overweight at Piper Sandler
- 11/02/22 Cowen
- Exelixis price target lowered to $21 from $26 at Cowen
- 10/31/22 EF Hutton
- Exelixis initiated with a Buy at EF Hutton
- 10/18/22 JMP Securities
- Exelixis initiated with an Outperform at JMP Securities
- 10/12/22 Guggenheim
- Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim
- 11/07/22 Raymond James
- Exact Sciences price target lowered to $60 from $70 at Raymond James
- 11/07/22 BTIG
- Exact Sciences price target lowered to $65 from $70 at BTIG
- 11/04/22 Baird
- Exact Sciences price target lowered to $60 from $75 at Baird
- 11/04/22 Citi
- Exact Sciences price target lowered to $35 from $50 at Citi
- 10/26/22 Morgan Stanley
- Bayer price target raised to EUR 81 from EUR 80 at Morgan Stanley
- 10/25/22 Capital One
- Arvinas initiated with an Overweight at Capital One
- 10/12/22 Redburn
- Bayer upgraded to Buy from Neutral at Redburn
- 09/07/22 Morgan Stanley
- Bayer price target lowered to EUR 80 from EUR 87 at Morgan Stanley
- 10/31/22 Oppenheimer
- BioMarin upgraded to Outperform from Perform at Oppenheimer
- 10/26/22 Piper Sandler
- Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
- 10/24/22 JPMorgan
- BioMarin price target lowered to $112 from $140 at JPMorgan
- 10/13/22 RBC Capital
- BioMarin price target raised to $95 from $90 at RBC Capital
- 11/02/22 Evercore ISI
- Evercore starts Legend Biotech with an Outperform on Carvykti potential
- 10/31/22 Guggenheim
- 2seventy Bio initiated with a Buy at Guggenheim
- 10/12/22 Barclays
- Bristol-Myers price target lowered to $66 from $69 at Barclays
- 10/10/22 Guggenheim
- Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
CALT Calliditas Therapeutics - 06/16/22 Kepler Cheuvreux
- Calliditas Therapeutics initiated with a Buy at Kepler Cheuvreux
- 06/02/22 Pareto
- Calliditas Therapeutics initiated with a Buy at Pareto
- 03/15/22 Citi
- Calliditas Therapeutics price target lowered to $76 from $84 at Citi
- 12/20/21 H.C. Wainwright
- Calliditas price target raised to $62 from $52 at H.C. Wainwright
- 10/24/22 Piper Sandler
- Mirum's LIVMARLI PFIC data shows superiority to Albireo's Bylvay, says Piper
- 10/12/22 H.C. Wainwright
- Albireo Pharma price target raised to $68 from $54 at H.C. Wainwright
- 10/12/22 Baird
- Albireo Pharma price target raised to $55 from $43
- 10/11/22 Piper Sandler
- Piper says Bylvay safety, efficacy look similar to Mirum's Livmarli
- 08/08/22 Cantor Fitzgerald
- Aligos Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- 05/05/22 SVB Securities
- Aligos Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
- 03/22/22 Piper Sandler
- Aligos Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- 01/07/22 JPMorgan
- Aligos Therapeutics downgraded to Neutral from Overweight at JPMorgan
- 07/28/22 H.C. Wainwright
- Alimera Sciences price target raised to $9 from $8 at H.C. Wainwright
- 05/10/22 H.C. Wainwright
- Alimera Sciences price target lowered to $8 from $10 at H.C. Wainwright
- 02/25/22 Alliance Global Partners
- Alimera price target lowered to $11 from $14.50 at Alliance Global Partners
- 02/25/22 H.C. Wainwright
- Alimera Sciences price target lowered to $10 from $12 at H.C. Wainwright
- 11/02/22 H.C. Wainwright
- Alnylam price target lowered to $415 from $430 at H.C. Wainwright
- 10/24/22 JPMorgan
- Alnylam price target lowered to $200 from $204 at JPMorgan
- 10/07/22 BMO Capital
- Alnylam's Oxlumo label expansion modest positive for franchise, says BMO Capital
- 10/03/22 Jefferies
- Alnylam price target raised to $232 from $218 at Jefferies
- 09/16/22 Guggenheim
- Altimmune price target lowered to $26 from $31 at Guggenheim
- 09/16/22 H.C. Wainwright
- Altimmune selloff post Phase 1 data overdone, says H.C. Wainwright
- 09/14/22 Evercore ISI
- Altimmune a 'reasonable buy on weakness,' says Evercore ISI
- 09/14/22 Piper Sandler
- Piper says conviction in pemvidutide stronger after call with Altimmune team
ASMB Assembly Biosciences - 10/24/22 Truist
- Assembly Biosciences downgraded to Hold from Buy at Truist
- 07/21/22 H.C. Wainwright
- Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
- 04/01/22 Truist
- Assembly Biosciences price target lowered to $12 from $15 at Truist
- 11/02/22 Chardan
- Axcella Health price target lowered to $5 from $7 at Chardan
- 11/02/22 H.C. Wainwright
- Axcella Health price target lowered to $8 from $10 at H.C. Wainwright
- 09/29/22 Roth MKM
- Roth reiterates $19 target on Axcella after 'encouraging' data
- 08/03/22 H.C. Wainwright
- Axcella Health price target lowered to $8 from $14 at H.C. Wainwright
- 11/02/22 Morgan Stanley
- Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
- 11/02/22 Deutsche Bank
- Abiomed downgraded to Hold from Buy at Deutsche Bank
- 11/01/22 Piper Sandler
- Abiomed downgraded to Neutral from Overweight at Piper Sandler
- 11/01/22 Cowen
- Cowen starts Legend Biotech with an Outperform on Carvykti potential
- 11/03/22 UBS
- Ipsen price target raised to EUR 107 from EUR 102 at UBS
- 11/01/22 Societe Generale
- Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
- 10/31/22 Societe Generale
- Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
- 10/28/22 RBC Capital
- Ipsen price target raised to EUR 108 from EUR 107 at RBC Capital
- 09/23/22 H.C. Wainwright
- Inventiva price target lowered to $36 from $42 at H.C. Wainwright
- 03/09/22 Roth MKM
- Roth Capital sees Inventiva as 'attractive acquisition target'
- 11/22/21 H.C. Wainwright
- Inventiva price target raised to $42 from $40 at H.C. Wainwright
- 10/27/22 Oppenheimer
- Simulations Plus price target lowered to $65 from $75 at Oppenheimer
- 07/07/22 Craig-Hallum
- Simulations Plus price target raised to $60 from $55 at Craig-Hallum
- 01/03/22 Sidoti
- Simulations Plus reinstated with a Neutral at Sidoti
SMMNY Siemens Healthineers - 10/18/22 Morgan Stanley
- Siemens Healthineers initiated with an Overweight at Morgan Stanley
- 10/04/22 Barclays
- Siemens Healthineers price target lowered to EUR 62 from EUR 64 at Barclays
- 08/25/22 UBS
- Siemens Healthineers upgraded to Buy from Neutral at UBS
- 08/05/22 Societe Generale
- Siemens Healthineers price target lowered to EUR 62.90 from EUR 64.20 at Societe Generale
- 10/14/22 Societe Generale
- Siemens downgraded on 'too complacent' consensus at Societe Generale
- 10/14/22 Societe Generale
- Siemens downgraded to Hold from Buy at Societe Generale
- 10/04/22 Deutsche Bank
- Siemens price target lowered to EUR 145 from EUR 160 at Deutsche Bank
- 10/03/22 Barclays
- Siemens price target lowered to EUR 90 from EUR 95 at Barclays
- 11/03/22 Baird
- Ultragenyx upgraded to Outperform from Neutral at Baird
- 11/03/22 Cowen
- Ultragenyx price target lowered to $65 from $86 at Cowen
- 11/03/22 Credit Suisse
- Ultragenyx price target lowered to $96 from $105 at Credit Suisse
- 10/13/22 Guggenheim
- Ultragenyx upgraded to Buy from Neutral at Guggenheim
- 10/06/22 Barclays
- PerkinElmer price target lowered to $120 from $140 at Barclays
- 09/12/22 Barclays
- PerkinElmer price target lowered to $140 from $149 at Barclays
- 08/24/22 Credit Suisse
- PerkinElmer initiated with a Neutral at Credit Suisse
- 08/18/22 Stifel
- PerkinElmer downgraded to Hold on CFO exit at Stifel
- 11/03/22 Credit Suisse
- Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
- 10/14/22 Barclays
- Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
- 09/28/22 Oddo BHF
- Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
- 09/14/22 Piper Sandler
- Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
- 10/14/22 Barclays
- GSK price target lowered to 1,450 GBp from 1,800 GBp at Barclays
- 10/12/22 Morgan Stanley
- GSK price target raised to 1,650 GBp from 1,550 GBp at Morgan Stanley
- 09/29/22 Oddo BHF
- GSK upgraded to Outperform from Neutral at Oddo BHF
- 09/22/22 Evercore ISI
- Evercore upgrades Spero, quadruples target on GSK partnership
- 11/01/22 Guggenheim
- AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
- 10/31/22 Maxim
- Gilead price target raised to $92 from $84 at Maxim
- 10/31/22 Barclays
- Gilead upgraded to Equal Weight from Underweight at Barclays
- 10/28/22 BMO Capital
- Gilead price target raised to $72 from $63 at BMO Capital
- 11/03/22
- Vir Biotechnology reports Q3 EPS $1.30, consensus (21c)
- 08/09/22
- Vir Biotechnology reports Q2 EPS (58c), consensus 10c
- 08/11/22
- Surrozen reports Q2 EPS (40c) vs (69c) last year
- 05/11/22
- Surrozen reports Q1 EPS (23c), consensus (50c)
- 10/26/22
- Simulations Plus sees FY23 EPS 63c-67c, consensus 71c
- 10/26/22
- Simulations Plus reports Q4 EPS 5c, consensus 7c
- 07/06/22
- Simulations Plus backs FY22 revenue view $52M-$53M, consensus $52.9M
- 07/06/22
- Simulations Plus reports Q3 EPS 20c, consensus 17c
- 11/02/22
- Ultragenyx reports Q3 EPS ($3.50), consensus ($1.81)
- 07/28/22
- Ultragenyx reports Q2 EPS ($2.26), consensus ($1.75)
- 08/01/22
- PerkinElmer raises FY22 adjusted EPS view to $7.80-$7.90 from $6.80-$7.00
- 08/01/22
- PerkinElmer sees Q3 adjusted EPS $1.40-1.45, consensus $1.34
- 08/01/22
- PerkinElmer reports Q2 adjusted EPS $2.32, consensus $2.02
- 11/02/22
- Novo Nordisk reports 9-month EPS DKK18.42 vs. DKK15.98 last year
- 08/03/22
- Novo Nordisk raises 2022 sales growth outlook to 12%-16%
- 08/03/22
- Novo Nordisk reports Q2 EBIT DKK 18.39B, consensus DKK 18.13B
- 11/01/22
- Eli Lilly cuts FY22 EPS view to $7.70-$7.85 from $7.90-$8.05, consensus $7.99
- 11/01/22
- Eli Lilly reports Q3 EPS $1.98, consensus $1.96
- 10/31/22
- Notable companies reporting before tomorrow's open
- 11/07/22
- Ligand sees FY22 adjusted EPS $2.05-$2.20, consensus $2.79
- 11/07/22
- Ligand reports Q3 adjusted EPS 41c, consensus 43c
- 08/08/22
- Ligand boosts FY22 revenue view for combined business
- 08/08/22
- Ligand reports Q2 adjusted EPS $1.03, consensus 43c
- 08/17/22
- Kamada reaffirms FY22 revenue view $125M-$135M
- 08/17/22
- Kamada reports Q2 EPS (9c) vs 2c last year
- 05/17/22
- Kamada reaffirms FY22 revenue view $125M-$135M
- 05/17/22
- Kamada reports Q1 EPS (4c) vs 6c last year
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
- 11/02/22
- GSK reports Q3 adjusted EPS 46.9p, up 25% AER, 11% CER
- 07/27/22
- GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
- 07/29/22
- Galecto reports Q2 EPS (67c) vs. (49c) last year
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- 08/02/22
- Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70
- 11/01/22
- Exelixis sees FY22 revenue $1.575B-$1.6B, consensus $1.6B
- 11/01/22
- Exelixis reports Q3 adjusted EPS 31c, consensus 19c
- 08/09/22
- Exelixis reports Q2 EPS 28c, consensus 19c
- 05/10/22
- Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B
- 11/03/22
- Exact Sciences raises FY22 revenue view to $2.025B-$2.042B, consensus $2.01B
- 11/03/22
- Exact Sciences reports Q3 EPS (84c), consensus ($1.08)
- 08/02/22
- Exact Sciences lowers FY22 revenue view to $1.980B-$2.022B from $1.985B-$2.032B
- 08/02/22
- Exact Sciences reports Q2 EPS (94c), consensus ($1.07)
- 10/25/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51
- 10/25/22
- Bristol-Myers reports Q3 EPS $1.99, consensus $1.83
- 10/26/22
- BioMarin backs FY22 revenue view $2.06B-$2.16B, consensus $2.12B
- 10/26/22
- BioMarin reports Q3 GAAP EPS (4c), consensus (1c)
- 10/26/22
- Notable companies reporting after market close
- 08/03/22
- BioMarin raises FY22 revenue view to $2.06B-$2.16B from $2.05B-$2.15B
- 08/04/22
- Bayer raises FY core EPS view to EUR7.30 vs. EUR7.00 previously
- 08/04/22
- Bayer reports Q2 core EPS EUR1.93 vs. EUR1.61 last year
- 05/10/22
- Bayer reports Q1 core EPS EUR 3.53 vs. EUR 2.59 last year
- 11/01/22
- Axcella Health reports Q3 EPS (34c), consensus (38c)
- 08/12/22
- Axcella Health reports Q2 EPS (40c), consensus (38c)
ASMB Assembly Biosciences - 08/09/22
- Assembly Biosciences reports Q2 EPS (51c) vs. (55c) last quarter
- 05/12/22
- Assembly Biosciences reports Q1 EPS (48c), consensus (47c)
- 08/11/22
- Altimmune reports Q2 EPS (42c) vs (60c) last year
- 05/12/22
- Altimmune reports Q1 EPS (44c), consensus (58c)
- 10/27/22
- Alnylam reports Q3 EPS ($1.58), consensus ($1.77)
- 07/28/22
- Alnylam reports Q2 EPS ($2.03), consensus ($1.63)
- 07/27/22
- Alimera Sciences reports Q2 EPS (45c), consensus (55c)
- 05/09/22
- Alimera Sciences reports Q1 EPS (85c) vs (63c) last year
- 11/02/22
- Aligos Therapeutics reports Q3 EPS (44c), consensus (58c)
- 08/15/22
- Albireo Pharma reports Q2 EPS ($2.04), consensus ($1.65)
- 05/16/22
- Albireo Pharma reports Q1 EPS ($2.19), consensus ($1.85)
- 09/16/22
- WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports
- 06/27/22
- VW close to deal to sell Electrify America interest to Siemens, WSJ reports
- 07/09/22
- Eli Lilly's growth set to soar under CEO Ricks, Barron's says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 10/11/22
- New quality issues found at Eli Lilly drug plant, Reuters reports
- 08/13/22
- Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says
- 08/03/22
- Eli Lilly to begin commercial sales of COVID-19 antibody, WSJ reports
- 11/07/22
- Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says
- 10/20/22
- CDC panel says COVID shots to be added to regular vaccinations, WSJ says
- 10/18/22
- Johnson & Johnson likely to make 'modest' cuts to workforce, WSJ reports
- 08/20/22
- Buy Haleon on steady growth, planned dividend, Barron's says
- 08/17/22
- Generic drugmakers paid to settle first Zantac case before trial, Bloomberg says
- 06/24/22
- Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says
- 06/14/22
- FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says
- 05/28/22
- Buy Bristol-Myers, rally just getting started, Barron's says
- 09/13/22
- Bayer quietly starts search for new CEO, Bloomberg reports
- 06/27/22
- Supreme Court lets $87M award against Bayer for Roundup stand, Bloomberg reports
- 06/21/22
- Supreme Court rejects Bayer bid to end Roundup suits, Bloomberg reports
- 05/11/22
- Biden administration asks Supreme Court to reject Roundup appeal, Reuters says
- 08/09/22
- Fly Intel: After-Hours Movers
- 11/03/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/19/22
- What You Missed On Wall Street On Tuesday
- 07/19/22
- What You Missed On Wall Street This Morning
- 08/01/22
- What You Missed On Wall Street On Monday
- 08/01/22
- What You Missed On Wall Street This Morning
- 08/01/22
- Fly Intel: Pre-market Movers
- 07/05/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/03/22
- Biotech Alert: Searches spiking for these stocks today
- 09/01/22
- What You Missed On Wall Street On Thursday
- 09/01/22
- What You Missed On Wall Street This Morning
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 11/01/22
- What You Missed On Wall Street This Morning
- 11/01/22
- Fly Intel: Pre-market Movers
- 10/18/22
- What You Missed On Wall Street On Tuesday
- 11/04/22
- Biotech Alert: Searches spiking for these stocks today
- 05/17/22
- What You Missed On Wall Street This Morning
- 11/02/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/26/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/03/22
- Biotech Alert: Searches spiking for these stocks today
- 09/23/22
- What You Missed On Wall Street On Friday
- 09/23/22
- What You Missed On Wall Street This Morning
- 09/16/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street This Morning
- 10/04/22
- Fly Intel: Pre-market Movers
- 11/04/22
- What You Missed On Wall Street On Friday
- 11/04/22
- What You Missed On Wall Street This Morning
- 10/19/22
- What You Missed On Wall Street On Wednesday
- 10/19/22
- What You Missed On Wall Street This Morning
- 10/26/22
- What You Missed On Wall Street On Wednesday
- 10/26/22
- What You Missed On Wall Street This Morning
- 10/26/22
- Fly Intel: Pre-market Movers
- 10/20/22
- Meet PDS Biotechnology: Fly exclusive interview with CEO Frank Bedu-Addo
- 11/05/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 10/31/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/26/22
- Fly Intel: After-Hours Movers
- 10/12/22
- Fly Intel: After-Hours Movers
- 09/13/22
- What You Missed On Wall Street On Tuesday
- 09/13/22
- What You Missed On Wall Street This Morning
- 06/27/22
- What You Missed On Wall Street On Monday
- 06/27/22
- What You Missed On Wall Street This Morning
- 09/14/22
- What You Missed On Wall Street On Wednesday
- 09/14/22
- What You Missed On Wall Street This Morning
- 09/14/22
- Fly Intel: Pre-market Movers
- 09/09/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/03/22
- What You Missed On Wall Street On Wednesday
- 08/03/22
- What You Missed On Wall Street This Morning
- 08/03/22
- Fly Intel: Pre-market Movers
- 10/13/22
- Biotech Alert: Searches spiking for these stocks today
- 08/16/22
- What You Missed On Wall Street On Tuesday
- 08/16/22
- What You Missed On Wall Street This Morning
- 08/16/22
- Fly Intel: Pre-market Movers
- 08/01/22
- Early notable gainers among liquid option names on August 1st
- 07/21/22
- Early notable gainers among liquid option names on July 21st
- 11/01/22
- Unusually active option classes on open November 1st
- 10/03/22
- Eli Lilly And Co put volume heavy and directionally bearish
- 09/28/22
- Early notable gainers among liquid option names on September 28th
- 09/28/22
- Unusually active option classes on open September 28th
- 10/18/22
- Unusually active option classes on open October 18th
- 09/20/22
- Johnson & Johnson put volume heavy and directionally bearish
- 07/19/22
- Unusually active option classes on open July 19th
- 06/28/22
- Johnson & Johnson put volume heavy and directionally bearish
- 11/07/22
- GSK Pharma put volume heavy and directionally bearish
- 11/02/22
- Unusually active option classes on open November 2nd
- 09/23/22
- GSK Pharma call volume above normal and directionally bullish
- 08/15/22
- GSK plc (ADR) call volume above normal and directionally bullish
- 10/28/22
- Early notable gainers among liquid option names on October 28th
- 10/27/22
- Gilead options imply 2.6% move in share price post-earnings
- 09/30/22
- Unusually active option classes on open September 30th
- 08/02/22
- EXACT Sciences options imply 7.0% move in share price post-earnings
- 09/29/22
- Early notable gainers among liquid option names on September 29th
- 09/12/22
- Early notable gainers among liquid option names on September 12th
- 09/12/22
- Unusually active option classes on open September 12th
- 09/08/22
- Notable open interest changes for September 8th
- 09/13/22
- Altimmune call volume above normal and directionally bullish
- 09/12/22
- Altimmune put volume heavy and directionally bearish
|